AstraZeneca trial flop raises bigger question: Is its pipeline premium becoming more vulnerable? Shares down 6% worst day in 2 years. #AZN
#Biotech
$AZN (+0,29 %)
1Sem.·
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
2